DPPC-coated lipid nanoparticles as an inhalable carrier for accumulation of resveratrol in the pulmonary vasculature, a new strategy for pulmonary arterial hypertension treatment

References

• Amri A, Chaumeil JC, Sfar S, et al. (2012). Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release 158:182–93.
   PubMed Web of Science ®Google Scholar
• Csiszar A, Smith K, Labinskyy N, et al. (2006). Resveratrol attenuates TNFalfa-induced activation of coronary arterial endothelial cells: role of NF-kB inhibition. Am J Physiol Heart Circ Physiol 291:H1694–H1699.
   PubMed Web of Science ®Google Scholar
• Deus CM, Serafim TL, Magalhães-Novais S, et al. (2017). Magalh Es-Novais S. Sirtuin 1-dependent resveratrol cytotoxicity and pro-differentiation activity on breast cancer cells. Arch Toxicol 91:1261–78.
   PubMed Web of Science ®Google Scholar
• Dwivedi MV, Harishchandra RK, Koshkina O, et al. (2014). Size influences the effect of hydrophobic nanoparticles on lung surfactant model systems. Biophys J 106:289–98.
   PubMed Web of Science ®Google Scholar
• Epstein FH, Gibbons GH, Dzau VJ. (1994). The emerging concept of vascular remodeling. N Engl J Med 330:1431–8.
   PubMed Web of Science ®Google Scholar
• Feng AL, Boraey MA, Gwin MA, et al. (2011). Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. Int J Pharm 409:156–63.
   PubMed Web of Science ®Google Scholar
• Fuggetta MP, Bordignon V, Cottarelli A, et al. (2016). Downregulation of proinflammatory cytokines in HTLV-1-infected T cells by Resveratrol. J Exp Clin Cancer Res 35:118.
   PubMed Web of Science ®Google Scholar
• Guagliardo R, Pérez-Gil J, Smedt SD, et al. (2018). Pulmonary surfactant and drug delivery: Focusing on the role of surfactant proteins. J Control Release 291:116–26.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Humbert M, Souza R, et al. (2016). A global view of pulmonary hypertension. Lancet Respir Med 4:306–22.
   PubMed Web of Science ®Google Scholar
• Hu LD, Jia Y, Wen D. (2010). Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery. Pharmazie 65:585–7.
   PubMed Web of Science ®Google Scholar
• Hu X, Yang F-F, Wei X-L, et al. (2017). Curcumin acetate nanocrystals for sustained pulmonary delivery: preparation, characterization and in vivo evaluation. J Biomed Nanotechnol 13:99–109.
   PubMed Web of Science ®Google Scholar
• Humbert M, Lau EMT, Montani D, et al. (2014). Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 130:2189–208.
   PubMed Web of Science ®Google Scholar
• Illaro Uranga A, Ibarra Barrueta O, Oribe Ibanez M, et al. (2014). Treatment of pulmonary hypertension. Ital J Pediatr 40:A51–A51.
   PubMedGoogle Scholar
• Lei Y, Yingfeng T, Xueling J, et al. (2017). Resveratrol protects against pulmonary arterial hypertension in rats via activation of silent information regulator 1. Cell Physiol Biochem 42:55–67.
   PubMedGoogle Scholar
• Mahmud A, Discher DE. (2011). Lung vascular targeting through inhalation delivery:insight from filamentous viruses and other shapes. Iubmb Life 63:607–12.
   PubMed Web of Science ®Google Scholar
• Martignoni I, Trotta V, Lee W-H, et al. (2016). Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization and in vitro deposition study. J Microencapsul 33:735–42.
   PubMed Web of Science ®Google Scholar
• Martins S, Costa-Lima S, Carneiro T, et al. (2012). Solid lipid nanoparticles as intracellular drug transporters: An investigation of the uptake mechanism and pathway. Int J Pharm 430:216–27.
   PubMed Web of Science ®Google Scholar
• Mclaughlin VV, McGoon MD. (2006). Pulmonary arterial hypertension. Circulation 114:1417–31.
   PubMed Web of Science ®Google Scholar
• Musazzi UM, Youm I, Murowchick JB, et al. (2014). Resveratrol-loaded nanocarriers: formulation, optimization, characterization and in vitro toxicity on cochlear cells. Colloids Surf B Biointerfaces 118:234–42.
   PubMed Web of Science ®Google Scholar
• Nakayama H, Yaguchi T, Yoshiya S, et al. (2012). Resveratrol induces apoptosis MH7A human rheumatoid arthritis synovial cells in a sirtuin 1-dependent manner. Rheumatol Int 32:151–7.
   PubMed Web of Science ®Google Scholar
• Pyne NJ, Pyne S. (2017). Sphingosine kinase 1: a potential therapeutic target in pulmonary arterial hypertension?. Trends Mol Med 23:786–98.
   PubMed Web of Science ®Google Scholar
• R. Neves A, Lucio M, L.C. Lima J, et al. (2012). Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. CMC 19:1663–81.
   PubMed Web of Science ®Google Scholar
• Scalia S, Young PM, Traini D. (2014). Solid lipid microparticles as an approach to drug delivery. Expert Opin Drug Deliv 12:1–17.
   PubMed Web of Science ®Google Scholar
• Shuang Z, Meng-Tao L, Yu-Yan J, et al. (2015). Regulation of cell cycle regulators by SIRT1 contributes to resveratrol-mediated prevention of pulmonary arterial hypertension. Biomed Res Int 2015:1–14.
   Web of Science ®Google Scholar
• Sun J, Wang F, Sui Y, et al. (2012). Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q10 as naked nanocrystals. Int J Nanomedicine 7:5733–44.
   PubMed Web of Science ®Google Scholar
• Thompson AAR, Lawrie A. (2017). Targeting vascular remodeling to treat pulmonary arterial hypertension. Trends Mol Med 23:31–45.
   PubMed Web of Science ®Google Scholar
• Ungvari Z, Orosz Z, Rivera A, et al. (2007). Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol 292:H2417–H2424.
   PubMed Web of Science ®Google Scholar
• Walle T, Hsieh F, Delegge MH, et al. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377–82.
   PubMed Web of Science ®Google Scholar
• Yacoub MH, McLeod C. (2018). The expanding role of implantable devices to monitor heart failure and pulmonary hypertension. Nat Rev Cardiol 15:770–9.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chen H-Z, Wan Y-z, et al. (2011). Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ Res 109:639–48.
   PubMed Web of Science ®Google Scholar